The meaning of the anti-cancer antibody CLN-IgG (Pritumumab) generated by human × human hybridoma technology against the cyto-skeletal protein, vimentin, in the course of the treatment of malignancy.

MLA

Hugwil, Albert V. “The Meaning of the Anti-Cancer Antibody CLN-IgG (Pritumumab) Generated by Human × Human Hybridoma Technology against the Cyto-Skeletal Protein, Vimentin, in the Course of the Treatment of Malignancy.” Medical Hypotheses, vol. 81, no. 3, Sept. 2013, pp. 489–95. EBSCOhost, https://doi.org/10.1016/j.mehy.2013.05.037.

APA

Hugwil, A. V. (2013). The meaning of the anti-cancer antibody CLN-IgG (Pritumumab) generated by human × human hybridoma technology against the cyto-skeletal protein, vimentin, in the course of the treatment of malignancy. Medical Hypotheses, 81(3), 489–495. https://doi.org/10.1016/j.mehy.2013.05.037

Chicago

Hugwil, Albert V. 2013. “The Meaning of the Anti-Cancer Antibody CLN-IgG (Pritumumab) Generated by Human × Human Hybridoma Technology against the Cyto-Skeletal Protein, Vimentin, in the Course of the Treatment of Malignancy.” Medical Hypotheses 81 (3): 489–95. doi:10.1016/j.mehy.2013.05.037.